Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Retained Earnings: 2013-2024

Historic Retained Earnings for Fortress Biotech (FBIO) over the last 12 years, with Dec 2024 value amounting to -$740.9 million.

  • Fortress Biotech's Retained Earnings rose 0.54% to -$730.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$730.1 million, marking a year-over-year increase of 0.54%. This contributed to the annual value of -$740.9 million for FY2024, which is 6.62% down from last year.
  • Latest data reveals that Fortress Biotech reported Retained Earnings of -$740.9 million as of FY2024, which was down 6.62% from -$694.9 million recorded in FY2023.
  • Fortress Biotech's Retained Earnings' 5-year high stood at -$482.8 million during FY2020, with a 5-year trough of -$740.9 million in FY2024.
  • Moreover, its 3-year median value for Retained Earnings was -$694.9 million (2023), whereas its average is -$690.0 million.
  • Data for Fortress Biotech's Retained Earnings shows a maximum YoY declined of 15.85% (in 2022) over the last 5 years.
  • Fortress Biotech's Retained Earnings (Yearly) stood at -$482.8 million in 2020, then dropped by 13.40% to -$547.5 million in 2021, then fell by 15.85% to -$634.2 million in 2022, then declined by 9.56% to -$694.9 million in 2023, then declined by 6.62% to -$740.9 million in 2024.